ReviewJournal of neuro-oncology2025
Long-term quality of life and hypothalamic dysfunction after craniopharyngioma.
Review in Journal of neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Apc-deficient pituitary stem cells drive adamantinomatous craniopharyngioma through senescence-associated inflammation.EMBO molecular medicine · 2026Article
- Hypothalamic obesity in pediatric vs. adult craniopharyngioma: mechanisms, management, and cardiometabolic outcomes.Pituitary · 2026Review
- Hypothalamic syndrome and acquired hypothalamic obesity: from fragmented care to integrated multidisciplinary management.Pituitary · 2026Review
- Review
- Arginine Vasopressin Deficiency and Oxytocin Deficiency in the Endocrine Clinic.The Journal of clinical endocrinology and metabolism · 2026Review
- Treatment Priorities in Craniopharyngioma: Perspectives of Survivors and Caregivers.Biomedicines · 2026Article
- PROX1-associated lymphatic reprogramming signatures in pediatric adamantinomatous craniopharyngioma: a comparative study with adult cases.Frontiers in pediatrics · 2026Article
- Quality of life, morbidity, mortality, and long-term prognosis after craniopharyngioma.Frontiers in endocrinology · 2026Review
- Hunger, satiety, and eating behavior after craniopharyngioma - narrative review on current management and future therapeutic perspectives.Frontiers in endocrinology · 2026Review
- Postoperative weight gain following endoscopic endonasal surgery for craniopharyngiomas in children and adults: A retrospective cohort study.Pituitary · 2025Article
- Sleep Disorders, Dysregulation of Circadian Rhythms, and Fatigue After Craniopharyngioma-A Narrative Review.Biomedicines · 2025Review
- Semaglutide treatment in hypothalamic obesity: Two-Year outcomes on body composition, appetite, and quality of life.Pituitary · 2025Article
- Setmelanotide-mediated MC4R activation improves hypothalamic obesity via CaMKK2/AMPK pathways.Frontiers in pharmacology · 2025Article
- Hypothalamic obesity following craniopharyngioma surgery: What is the role of hypothalamic T2 signal changes in brain MRI?Neuro-oncology advancesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
backgroundAfter diagnosis and management of childhood-onset craniopharyngioma, patients frequently develop a rapid weight gain starting in the first 6-12 months after diagnosis and leading to morbid hypothalamic obesity due to disease- and/or treatment-associated hypothalamic lesions.
methodsA scoping review was performed after search of the MEDLINE/PubMed, Embase, and Web of Science databases for initial identification of articles. The search terms craniopharyngioma, hypothalamic obesity, and quality of life were used.
resultsHypothalamic obesity should be diagnosed and treated in the context of hypothalamic syndrome. Hypothalamic nuclei are the key-regulators of our body homeostasis. Hypothalamic syndrome includes endocrine deficiencies of hypothalamic-pituitary axes, disruption of circadian rhythm, disturbed hunger-satiety and thirst feelings, temperature dysregulation, and neurocognitive, sleep and psychosocial behavioral problems. Consequently, patients with hypothalamic syndrome develop hypothalamic obesity, chronic fatigue, increased daytime sleepiness and mood disorders resulting in isolation, school drop-out and inability to participate in daily life. Long-term follow-up is frequently impaired by increased risk for metabolic syndrome, cardiovascular health problems, severe impairments of health-related quality of life, and premature mortality. Treatment of hypothalamic syndrome is challenging. Hypothalamic syndrome is not a ,one-size-fits-all- disease, which may not require a ,one-size-fits-all- management. Recently, an algorithm for personalized, risk-specific treatment of hypothalamic syndrome after CP has been published. Dextro-amphetamines and other central stimulating agents (modafinil, methylphenidate) may cause weight loss, especially in children with hyperphagia or decreased resting-energy expenditure. Reports on the use of glucagon-like peptide-1 receptor (GLP-1R) agonists for acquired hypothalamic obesity have been contradictory, with successful reports but also series with limited results. Bariatric surgery is effective. However, non-reversible procedures are controversial due to ethical and legal considerations in minors.
conclusionsHypothalamus-sparing treatment strategies and further research on novel therapeutic agents for hypothalamic syndrome are warranted.
Indexed as
Identifiers
40097882What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.